The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease

Simple item page
dc.contributor.authorBarrera Martínez, Francisco
dc.contributor.authorUribe, Javier
dc.contributor.authorOlvares, Nixa
dc.contributor.authorHuerta, Paula
dc.contributor.authorCabrera, Daniel
dc.contributor.authorRomero-Gomez, Manuel
dc.date.accessioned2025-01-20T16:13:42Z
dc.date.available2025-01-20T16:13:42Z
dc.date.issued2024
dc.description.abstractMetabolic Dysfunction-Associated Fatty Liver Disease and Diabetes Mellitus are two prevalent metabolic disorders that often coexist and synergistically contribute to the progression of each other. Several pathophysiological pathways are involved in the association, including insulin resistance, inflammation, and lipotoxicity, providing a foundation for understanding the complex interrelationships between these conditions. The presence of MASLD has a significant impact on diabetes risk and the development of microvascular and macrovascular complications, and diabetes significantly contributes to an increased risk of liver fibrosis progression in MASLD and the development of hepatocellular carcinoma. Moreover, both pathologies have a synergistic effect on cardiovascular events and mortality. Therapeutic interventions targeting MASLD and diabetes are discussed, considering lifestyle modifications, pharmacological agents, and emerging treatment modalities. The review also addresses the challenges in managing these comorbidities, such as the need for personalized approaches and the potential impact on cardiovascular health. The insights gleaned from this analysis can inform clinicians, researchers, and policymakers in developing integrated strategies for preventing, diagnosing, and managing these metabolic disorders. (c) 2024 Published by Elsevier Espa & ntilde;a, S.L.U. on behalf of Fundaci & oacute;n Cl & iacute;nica M & eacute;dica Sur, A.C. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
dc.description.funderChilean government through the Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT)
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.aohep.2024.101501
dc.identifier.issn1665-2681
dc.identifier.urihttps://doi.org/10.1016/j.aohep.2024.101501
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/90401
dc.identifier.wosidWOS:001266356200001
dc.information.autorucEscuela de Medicina; Barrera Martínez, Francisco; 0000-0001-5334-1528; 14816
dc.issue.numero4
dc.language.isoen
dc.revistaAnnals of hepatology
dc.rightsacceso restringido
dc.subjectFatty liver
dc.subjectMetabolic associated fatty liver disease
dc.subjectMASLD
dc.subjectDiabetes
dc.subjectMetabolic syndrome
dc.subjectHepatic steatosis
dc.subjectInsulin resistance
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleThe Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
dc.typeartículo
dc.volumen29
sipa.codpersvinculados14816
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas